Panagiotis Maghsoudlou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Panagiotis Maghsoudlou has a total of 285 co-authors. Here are the top co-authors by number of shared publications:
- Paolo De Coppi
Department of Development and Regeneration, Cluster Woman and Child, Biomedical Sciences, My FetUZ Fetal Research Center, KU Leuven, Leuven, Belgium
28 shared publications - Simon Eaton
Great Ormond Street Institute of Child Health University College London London UK
13 shared publications - Luca Urbani
The Roger Williams Institute of Hepatology, Foundation for Liver Research, London SE5 9NT, UK
12 shared publications Giorgia Totonelli
Great Ormond Street Institute of Child Health, UCL, London, United Kingdom
10 shared publications- Panicos Shangaris
Department of Women and Children’s Health, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UK
7 shared publications Stavros P. Loukogeorgakis
UCL Institute of Child Health, UCL, London, United Kingdom
7 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- p. 1-8
Eighteen-month real-world outcomes of intravitreal aflibercept 8 mg in treatment-naïve neovascular age-related macular degeneration: a UK single-centre experience
Purpose: Intravitreal aflibercept 8 mg was developed to extend treatment intervals and reduce injection burden in neovascular age-related macular degeneration (nAMD). We evaluated visual, anatomical, and durability outcomes over 18 months in routine clinical practice. Methods: This retrospective observational study included 102 eyes of 95 treatment-naïve nAMD patients commencing aflibercept 8 mg at a UK tertiary centre. All eyes received three loading injections followed by a treat-and-extend protocol. Best-recorded visual acuity (BRVA), central subfield thickness (CST), intraretinal fluid (IRF), subretinal fluid (SRF), and macular haemorrhage were assessed at baseline, post-loading, 12 months, and 18 months. Linear and generalised mixed-effects models were applied. Results: Mean patient age was 81.1 ± 6.5 years; 68.4% were female. Mean BRVA was 62.5 ± 12.4 letters at baseline, 67.5 ± 13.7 post-loading, 66.8 ± 15.3 at 12 months ( n = 102), and 65.5 ± 18.5 letters at 18 months ( n = 73). Mean CST was 317.1 ± 95.4 μm at baseline, 237.9 ± 45.2 μm post-loading, 236.3 ± 51.7 μm at 12 months, and 220.6 ± 32.2 μm at 18 months ( n = 73). At 12 months, 51.9% of eyes achieved treatment intervals of ≥ 12 weeks, increasing to 73.9% at 18 months. No cases of endophthalmitis were recorded. Conclusion: Aflibercept 8 mg achieved sustained visual acuity, significant anatomical improvement, and progressively extended treatment intervals over 18 months in treatment-naïve nAMD within routine clinical practice, supporting its effectiveness in reducing treatment burden without compromising disease control.
- 30 September 2026
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- p. 1-8
Open AccessEighteen-month real-world outcomes of intravitreal aflibercept 8 mg in treatment-naïve neovascular age-related macular degeneration: a UK single-centre experience
Purpose: Intravitreal aflibercept 8 mg was developed to extend treatment intervals and reduce injection burden in neovascular age-related macular degeneration (nAMD). We evaluated visual, anatomical, and durability outcomes over 18 months in routine clinical practice. Methods: This retrospective observational study included 102 eyes of 95 treatment-naïve nAMD patients commencing aflibercept 8 mg at a UK tertiary centre. All eyes received three loading injections followed by a treat-and-extend protocol. Best-recorded visual acuity (BRVA), central subfield thickness (CST), intraretinal fluid (IRF), subretinal fluid (SRF), and macular haemorrhage were assessed at baseline, post-loading, 12 months, and 18 months. Linear and generalised mixed-effects models were applied. Results: Mean patient age was 81.1 ± 6.5 years; 68.4% were female. Mean BRVA was 62.5 ± 12.4 letters at baseline, 67.5 ± 13.7 post-loading, 66.8 ± 15.3 at 12 months ( n = 102), and 65.5 ± 18.5 letters at 18 months ( n = 73). Mean CST was 317.1 ± 95.4 μm at baseline, 237.9 ± 45.2 μm post-loading, 236.3 ± 51.7 μm at 12 months, and 220.6 ± 32.2 μm at 18 months ( n = 73). At 12 months, 51.9% of eyes achieved treatment intervals of ≥ 12 weeks, increasing to 73.9% at 18 months. No cases of endophthalmitis were recorded. Conclusion: Aflibercept 8 mg achieved sustained visual acuity, significant anatomical improvement, and progressively extended treatment intervals over 18 months in treatment-naïve nAMD within routine clinical practice, supporting its effectiveness in reducing treatment burden without compromising disease control.
- Open Access
- 11 September 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1976368
Correction: The immunopathogenesis of uveitis
- 11 September 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1976368
Open AccessCorrection: The immunopathogenesis of uveitis
- 30 June 2026
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 34 (7) , 1-8
Choroidal and Retinal Imaging Findings in Childhood-Onset Mevalonate Kinase Deficiency: An OCT-Based Case–Control Study
To compare macular microvascular and microstructural exploratory imaging findings in patients with childhood-onset mevalonate kinase deficiency (MKD) and healthy controls, and to assess associations with disease activity. This cross-sectional case-control study included patients with childhood-onset, genetically confirmed MKD and healthy controls. Disease activity was assessed using the autoinflammatory disease activity index (AIDAI) score and C-reactive protein (CRP) levels. Choroidal images were obtained to measure subfoveal choroidal thickness (SFCT) and to calculate the total choroidal area (TCA), luminal area (LA), stromal area (SA), and the choroidal vascularity index (CVI). Macular optical coherence tomography (OCT) and optical coherence tomography-angiography (OCT-A) parameters were compared between groups, and associations with systemic disease activity were examined. The study included 17 patients with childhood-onset MKD and 30 healthy controls. The MKD group showed higher LA and CVI than in controls (p = 0.042 and p = 0.014, respectively), whereas TCA and SA were comparable between groups (p = 0.124 and p = 0.669, respectively). Mean central macular thickness was lower in the MKD group (p = 0.030), while SFCT was comparable between groups (p = 0.325). No significant differences were observed in macular microvascular parameters. Patients with childhood-onset MKD showed higher CVI, whereas macular microvascular parameters were comparable to those of controls. These findings may suggest subtle alterations in choroidal vascular composition, potentially related to the underlying inflammatory milieu; however, given that all patients were receiving canakinumab treatment, they should be interpreted cautiously as exploratory associations requiring confirmation in longitudinal studies.
- 30 June 2026
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 34 (7) , 1-8
Choroidal and Retinal Imaging Findings in Childhood-Onset Mevalonate Kinase Deficiency: An OCT-Based Case–Control Study
To compare macular microvascular and microstructural exploratory imaging findings in patients with childhood-onset mevalonate kinase deficiency (MKD) and healthy controls, and to assess associations with disease activity. This cross-sectional case-control study included patients with childhood-onset, genetically confirmed MKD and healthy controls. Disease activity was assessed using the autoinflammatory disease activity index (AIDAI) score and C-reactive protein (CRP) levels. Choroidal images were obtained to measure subfoveal choroidal thickness (SFCT) and to calculate the total choroidal area (TCA), luminal area (LA), stromal area (SA), and the choroidal vascularity index (CVI). Macular optical coherence tomography (OCT) and optical coherence tomography-angiography (OCT-A) parameters were compared between groups, and associations with systemic disease activity were examined. The study included 17 patients with childhood-onset MKD and 30 healthy controls. The MKD group showed higher LA and CVI than in controls (p = 0.042 and p = 0.014, respectively), whereas TCA and SA were comparable between groups (p = 0.124 and p = 0.669, respectively). Mean central macular thickness was lower in the MKD group (p = 0.030), while SFCT was comparable between groups (p = 0.325). No significant differences were observed in macular microvascular parameters. Patients with childhood-onset MKD showed higher CVI, whereas macular microvascular parameters were comparable to those of controls. These findings may suggest subtle alterations in choroidal vascular composition, potentially related to the underlying inflammatory milieu; however, given that all patients were receiving canakinumab treatment, they should be interpreted cautiously as exploratory associations requiring confirmation in longitudinal studies.
- Top Cited PapersOpen Access
- 2 March 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1717056
The Immunopathogenesis of uveitis
Uveitis encompasses a heterogeneous group of intraocular inflammatory disorders and remains a leading cause of preventable visual loss. Its immunopathogenesis reflects the interplay between a uniquely regulated ocular environment and triggers that breach or bypass that privilege. Much of our mechanistic understanding derives from animal models, which have helped define key features of ocular immune regulation. Layered mechanisms normally restrain inflammation: physical barriers (blood–aqueous and blood–retina), a locally immunosuppressive milieu, and systemic tolerance circuits such as anterior chamber–associated immune deviation. When these controls fail, disease emerges through a number of broad pathways. In autoimmune uveitis, genetic susceptibility (HLA class I/II and peptide-trimming enzymes such as ERAP) shapes antigen display and lowers activation thresholds for autoreactive T-cells. Antigen presentation in draining nodes primes Th1/Th17 responses. Within the eye, effector T-cells are restimulated by resident microglia and recruited macrophages, driving cytokine cascades that disrupt the blood–retina barrier and amplify leukocyte recruitment. B cells may augment tissue injury via antigen presentation, cytokine production, local antibody formation, and, in some entities, ectopic lymphoid structures. These mechanisms are largely defined in experimental autoimmune uveitis and form the basis for extrapolating human pathogenesis. Tissue-resident memory T-cells persist into remission and may influence relapse risk. Autoinflammatory uveitis arises from dysregulated innate pathways independent of antigen specificity. Infectious uveitis reflects direct intraocular infection or reactivation. Post-infectious inflammation may be sustained by antigen persistence or molecular mimicry. Paraneoplastic uveitis (autoimmune retinopathy) arises when anti-tumour immunity cross-reacts with retinal antigens. Therapy should mirror the dominant immunopathology. In infectious uveitis, clinicians first reduce pathogen load with targeted antimicrobials and then add anti-inflammatory therapy under antimicrobial cover; maintenance antivirals curb reactivation when indicated. In autoimmune disease, where Th1/Th17–macrophage circuits dominate, steroid-sparing treatment targets TNF and IL-6 pathways. In autoinflammatory forms, excess inflammasome/IL-1 signalling supports IL-1 blockade. Advances in humanised modelling will be key to defining condition-specific mechanisms and supporting the evolution of tailored interventions.
- 2 March 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1717056
Top Cited PapersOpen AccessThe Immunopathogenesis of uveitis
Uveitis encompasses a heterogeneous group of intraocular inflammatory disorders and remains a leading cause of preventable visual loss. Its immunopathogenesis reflects the interplay between a uniquely regulated ocular environment and triggers that breach or bypass that privilege. Much of our mechanistic understanding derives from animal models, which have helped define key features of ocular immune regulation. Layered mechanisms normally restrain inflammation: physical barriers (blood–aqueous and blood–retina), a locally immunosuppressive milieu, and systemic tolerance circuits such as anterior chamber–associated immune deviation. When these controls fail, disease emerges through a number of broad pathways. In autoimmune uveitis, genetic susceptibility (HLA class I/II and peptide-trimming enzymes such as ERAP) shapes antigen display and lowers activation thresholds for autoreactive T-cells. Antigen presentation in draining nodes primes Th1/Th17 responses. Within the eye, effector T-cells are restimulated by resident microglia and recruited macrophages, driving cytokine cascades that disrupt the blood–retina barrier and amplify leukocyte recruitment. B cells may augment tissue injury via antigen presentation, cytokine production, local antibody formation, and, in some entities, ectopic lymphoid structures. These mechanisms are largely defined in experimental autoimmune uveitis and form the basis for extrapolating human pathogenesis. Tissue-resident memory T-cells persist into remission and may influence relapse risk. Autoinflammatory uveitis arises from dysregulated innate pathways independent of antigen specificity. Infectious uveitis reflects direct intraocular infection or reactivation. Post-infectious inflammation may be sustained by antigen persistence or molecular mimicry. Paraneoplastic uveitis (autoimmune retinopathy) arises when anti-tumour immunity cross-reacts with retinal antigens. Therapy should mirror the dominant immunopathology. In infectious uveitis, clinicians first reduce pathogen load with targeted antimicrobials and then add anti-inflammatory therapy under antimicrobial cover; maintenance antivirals curb reactivation when indicated. In autoimmune disease, where Th1/Th17–macrophage circuits dominate, steroid-sparing treatment targets TNF and IL-6 pathways. In autoinflammatory forms, excess inflammasome/IL-1 signalling supports IL-1 blockade. Advances in humanised modelling will be key to defining condition-specific mechanisms and supporting the evolution of tailored interventions.
- Open Access
- 8 January 2026
- Published by Springer Nature in Eye
- Vol. 40 (3) , 288-289
The ADJUST trial and its implications for biologic discontinuation in juvenile idiopathic arthritis-associated uveitis
- 8 January 2026
- Published by Springer Nature in Eye
- Vol. 40 (3) , 288-289
Open AccessThe ADJUST trial and its implications for biologic discontinuation in juvenile idiopathic arthritis-associated uveitis
- Open Access
- 6 June 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 278, 38-51
Evidence and Consensus-Based Imaging Guidelines in Acute Posterior Multifocal Placoid Pigment Epitheliopathy (APMPPE) - Multimodal imaging in Uveitis (MUV) Taskforce Report 7
- 6 June 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 278, 38-51
Open AccessEvidence and Consensus-Based Imaging Guidelines in Acute Posterior Multifocal Placoid Pigment Epitheliopathy (APMPPE) - Multimodal imaging in Uveitis (MUV) Taskforce Report 7
- Open Access
- 21 April 2025
- Published by Springer Nature in Research Square
Evaluating Large Language Models for Quality Control in Research Ethics Review
Large Language Models (LLMs) could streamline research ethics and governance review by automating routine quality control checks. This study assessed Claude 3.5 Sonnet, ChatGPT4o, and Microsoft CoPilot in evaluating participant information sheets against Health Research Authority standards. Six clinical trial applications were processed using 32 standardised queries, with accuracy, processing time, error rates, and response quality assessed by two blinded reviewers. Claude showed the highest accuracy, detected more deviations from guidance, and had the fastest processing time (7.17 ± 0.68 min vs. ChatGPT 13.58 ± 2.2 min, CoPilot 23.25 ± 6.21 min). Hallucination rates were lowest in Claude, followed by ChatGPT and CoPilot. Claude also received the highest response quality ratings (77.6% “very good” vs. ChatGPT 56.7%, CoPilot 45.2%). While all three models were capable, Claude consistently outperformed the others, demonstrating the potential of LLM-assisted quality control while emphasizing the need for human oversight.
- 21 April 2025
- Published by Springer Nature in Research Square
Open AccessEvaluating Large Language Models for Quality Control in Research Ethics Review
Large Language Models (LLMs) could streamline research ethics and governance review by automating routine quality control checks. This study assessed Claude 3.5 Sonnet, ChatGPT4o, and Microsoft CoPilot in evaluating participant information sheets against Health Research Authority standards. Six clinical trial applications were processed using 32 standardised queries, with accuracy, processing time, error rates, and response quality assessed by two blinded reviewers. Claude showed the highest accuracy, detected more deviations from guidance, and had the fastest processing time (7.17 ± 0.68 min vs. ChatGPT 13.58 ± 2.2 min, CoPilot 23.25 ± 6.21 min). Hallucination rates were lowest in Claude, followed by ChatGPT and CoPilot. Claude also received the highest response quality ratings (77.6% “very good” vs. ChatGPT 56.7%, CoPilot 45.2%). While all three models were capable, Claude consistently outperformed the others, demonstrating the potential of LLM-assisted quality control while emphasizing the need for human oversight.
- Open Access
- 24 January 2025
- Published by Springer Nature in Eye
- Vol. 39 (4) , 796-797
Safety concerns regarding viscoelastic delivery systems, or, caveat injector
- 24 January 2025
- Published by Springer Nature in Eye
- Vol. 39 (4) , 796-797
Open AccessSafety concerns regarding viscoelastic delivery systems, or, caveat injector
- 6 November 2024
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 20 (12) , 795-808
The management of adult and paediatric uveitis for rheumatologists
Uveitis encompasses multiple different conditions that are all characterized by intra-ocular inflammation. Uveitis occurs in the context of many different rheumatological conditions and carries a substantial risk to vision. Uveitis can develop both at the early stages of rheumatic diseases, sometimes even preceding other clinical features, and at later stages of disease. Uveitis can also occur as either a direct or an indirect complication of therapies used to treat patients with rheumatic disease. Conversely, patients with uveitis of non-rheumatic aetiology sometimes require immunosuppression, a treatment option that is not readily accessible to ophthalmologists. Thus, collaborative working between rheumatologists and ophthalmologists is critical for optimal management of patients with uveitis. This Review is written with rheumatologists in mind, to assist in the care of patients with uveitis. We collate and summarize the latest evidence and best practice in the diagnosis, management and prognostication of uveitis, including future trends and research priorities.
- 6 November 2024
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 20 (12) , 795-808
The management of adult and paediatric uveitis for rheumatologists
Uveitis encompasses multiple different conditions that are all characterized by intra-ocular inflammation. Uveitis occurs in the context of many different rheumatological conditions and carries a substantial risk to vision. Uveitis can develop both at the early stages of rheumatic diseases, sometimes even preceding other clinical features, and at later stages of disease. Uveitis can also occur as either a direct or an indirect complication of therapies used to treat patients with rheumatic disease. Conversely, patients with uveitis of non-rheumatic aetiology sometimes require immunosuppression, a treatment option that is not readily accessible to ophthalmologists. Thus, collaborative working between rheumatologists and ophthalmologists is critical for optimal management of patients with uveitis. This Review is written with rheumatologists in mind, to assist in the care of patients with uveitis. We collate and summarize the latest evidence and best practice in the diagnosis, management and prognostication of uveitis, including future trends and research priorities.
- Open Access
- 26 November 2023
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 31 (10) , 1930-1943
Uveitis Associated with Monogenic Autoinflammatory Syndromes in Children
Monogenic autoinflammatory syndromes (MAISs), are caused by pathogenic genetic variants in the innate immune system, leading to dysregulation and aberrant inflammasome activation spontaneously or with minimal triggering. The diagnosis and treatment of MAISs can be intricate, relying on an increased recognition of potential differential diagnoses. This review examines the clinical features of MAIS, with a special focus on uveitis. It also evaluates treatment options and assesses the effects of activating molecular and cytokine pathways.
- 26 November 2023
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 31 (10) , 1930-1943
Open AccessUveitis Associated with Monogenic Autoinflammatory Syndromes in Children
Monogenic autoinflammatory syndromes (MAISs), are caused by pathogenic genetic variants in the innate immune system, leading to dysregulation and aberrant inflammasome activation spontaneously or with minimal triggering. The diagnosis and treatment of MAISs can be intricate, relying on an increased recognition of potential differential diagnoses. This review examines the clinical features of MAIS, with a special focus on uveitis. It also evaluates treatment options and assesses the effects of activating molecular and cytokine pathways.